CAR-T Cell Therapy Market to Grow at CAGR of 33.11% through 2026
Increasing prevalence of cancer and
widespread research activities are expected to drive global CAR-T cell therapy
market
According to TechSci Research
report, “Global CAR-T Cell Therapy Market, By Product Type
(Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus
(brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Abecma
(idecabtagene vicleucel), Others), By Tumor Type (Hematological Malignancies,
Solid Tumors), By Indication (Diffused Large B-cell Lymphoma (DLBCL), Acute
Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma
(MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By
Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User
(Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Others), By
Company (2020), By Region, Forecast & Opportunities, 2026”, Global CAR-T cell therapy market is expected
to reach USD6134.56 million by 2026 and to grow with a double digit CAGR of
33.11% over the forecast period. Key factors fueling the growth of global CAR-T cell therapy market
include rising prevalence of cancer around the globe and increasing need for
breakthrough therapeutic solutions. There is an increasing number of patients
who are showing response failure to alternative treatments. This factor is also
expected to foster the growth of global CAR-T cell therapy market in the coming
years. Moreover, rising R&D expenditure and boom in the field of
immuno-oncology are some other factors propelling the growth of this market.
Also, rising government initiatives for promoting research for cell therapy in
cancer and improving health care infrastructure are supporting the growth of
global CAR-T cell therapy market.
Additionally, increasing
clinical trials and development of new and effective therapy options are
driving the growth of this market. The effectiveness of CAR-T cell therapy in
treating cancer is anticipated to present huge growth opportunities for
pharmaceutical and biotech companies. However, the market might also face some
restrains. The complicated manufacturing process of CAR-T cells and high cost
of the treatment might hamper the market growth. Furthermore, side effects of
CAR-T cell therapy may lead to neurological problems and cytokine release
syndrome (CRS). This factor also might pose as a challenge for the growth of
global CAR-T cell therapy market.
Browse 159 Figures spread
through 110
Pages and an in-depth TOC on "Global CAR-T Cell Therapy Market."
https://www.techsciresearch.com/report/car-t-cell-therapy-market/5168.html
The global CAR-T cell therapy
market is segmented based on product type, tumor
type, indication, treatment type, targeted antigen, end user, company and region. Based on targeted antigen,
the market can be segmented into CD 19, BCMA (B-Cell Maturation Antigen) and
others. Among them, CD 19 antigen is expected to hold largest market share
during the forecast period as more companies are able to get their CD 19
antigens approved and have them commercially available. However, B-Cell
Maturation Antigen (BCMA) is anticipated to witness fastest CAGR through 2026
as they play a critical role in regulating B-cell proliferation and survival.
Based on end user, global
CAR-T cell therapy market can be segmented into Hospitals, Speciality Clinics,
Ambulatory Surgical Centres and others. Among them, Hospitals segment is
expected to witness high growth during the forecast period due to increasing
number of hospital establishments across the globe.
Major players operating in the
global CAR-T cell therapy market are Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Co., Cellectis
SA, Amgen Inc., Pfizer Inc., Merck & Co. Inc., Intellia Therapeutics Inc.,
Novartis AG, Poseida Therapeutics Inc., Johnson & Johnson SA, Allogene
Therapeutics Inc., Autolus Therapeutics PLC, Humanigen Inc., Sangamo
Therapeutics, Inc., among others. The companies are undergoing extensive research & development
activities to launch new CAR-T cell therapies in the market.
Download sample report @ https://www.techsciresearch.com/sample-report.aspx?cid=5168
Customers can also request for 10% free
customization on this report.
“North America dominated the
global CAR-T cell therapy market in 2020 and is expected to hold its dominance
through 2026 owing to large patient pool suffering from cancer in countries
such as United States and Canada. Also, rapid development and launch of new therapies
for the treatment of cancer by leading companies is making the region a
profitable market for manufactures. Following North America, Europe is
anticipated to be the second most prominent market for CAR-T cell therapy due
to extensive research for development of cancer therapies in the region,” said
Mr. Karan Chechi, Research Director with TechSci Research, a research based
global management consulting firm.
“Global CAR-T Cell
Therapy Market, By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah
(Tisagenlecleucel), Tecartus (brexucabtagene autoleucel), Breyanzi
(lisocabtagene maraleucel), Abecma (idecabtagene vicleucel), Others), By Tumor
Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large
B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular
Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single
Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell
Maturation Antigen), Others), By End User (Hospitals, Speciality Clinics,
Ambulatory Surgical Centers, Others), By Company (2020), By Region, Forecast
& Opportunities, 2026” has
evaluated the future growth potential of global CAR-T cell therapy market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in global CAR-T cell therapy market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/